Altın Duygu, Yalçın İbrahim, Khatib Ghanim, Dağgez Keleşoğlu Mine, Akgöl Sedat, Önder Ayşe Büşra, Kahramanoğlu İlker, Güvenal Tevfik, Topuz Samet, Demirkıran Fuat
Clinic of Obstetrics and Gynecology, Ordu University Training and Research Hospital, Ordu, Turkey
Clinic of Obstetrics and Gynecology, Şanlıurfa Training and Research Hospital, Şanlıurfa, Turkey
J Turk Ger Gynecol Assoc. 2020 Dec 4;21(4):265-271. doi: 10.4274/jtgga.galenos.2020.2020.0071.
This study aimed to investigate how gynecologic oncologists modified their patient management during Coronavirus disease-2019 (COVID-19) in Turkey.
An online survey was sent to gynecologic oncology specialists and fellows in Turkey. It included management questions about strategies for newly diagnosed or recurrent endometrial, cervical, ovarian and vulvar cancer during the pandemic. Participants were asked if treatment of these cancers can be delayed or not and, if yes, the duration of delay.
32.9% of surgeons prescribed oral or intrauterine progesterone for early stage, low-grade endometrial cancer. Conversely, 65.7% and 45.7% of the most surgeons did not change their management for early stage high-grade and advanced stage endometrial cancers respectively, as they perform surgery. 58% and 67.1% of the surgeons continued to prefer standard surgical treatment for microinvasive and early stage cervical cancers, respectively. Radiotherapy was preferred administered with hypofractionated doses for locally advanced cervical cancer (57.1%). While 67.1% of surgeons operated early stage ovarian cancer patients, 50% administered neoadjuvant chemotherapy (NACT) to all advanced stage ovarian cancers and 50% administered more cycles of NACT in preference to interval debulking surgery. 93.7% of the surgeons responded that treatment should not be delayed beyond eight weeks.
Most Turkish gynecologic oncologists modified their management of gynecologic cancers due to the COVID-19 pandemic. While chemotherapy was preferred for ovarian cancer, postponement of the surgery, with or without non-surgical options, was considered for early stage, low-grade endometrial cancer. Treatment of gynecologic cancers should be decided on a case by case basis, taking into account local COVID-19 infection rates and availability of health facilities. Prognosis is also an important consideration if delay is contemplated. Standard treatment and normal time-frames should be used if possible. If not, a postponement for a maximum of eight weeks or referral to another center were acceptable alternatives.
本研究旨在调查土耳其妇科肿瘤学家在2019年冠状病毒病(COVID-19)期间如何调整其患者管理方式。
向土耳其的妇科肿瘤学专家和研究员发送了一份在线调查问卷。问卷包含有关大流行期间新诊断或复发性子宫内膜癌、宫颈癌、卵巢癌和外阴癌治疗策略的管理问题。参与者被问及这些癌症的治疗是否可以推迟,若可以推迟,推迟的时长。
32.9%的外科医生为早期、低级别子宫内膜癌开了口服或宫内黄体酮。相反,大多数外科医生中分别有65.7%和45.7%对早期高级别和晚期子宫内膜癌未改变其管理方式,因为他们会进行手术。58%和67.1%的外科医生分别继续倾向于对微浸润性和早期宫颈癌采用标准手术治疗。对于局部晚期宫颈癌,57.1%的医生倾向于给予大分割剂量放疗。67.1%的外科医生对早期卵巢癌患者进行手术,50%的医生对所有晚期卵巢癌患者给予新辅助化疗(NACT),50%的医生更倾向于给予更多疗程的NACT而非间隔减瘤手术。93.7%的外科医生回答治疗不应推迟超过八周。
由于COVID-19大流行,大多数土耳其妇科肿瘤学家调整了他们对妇科癌症的管理方式。对于卵巢癌,化疗更受青睐,而对于早期、低级别子宫内膜癌,考虑推迟手术,无论是否有非手术选择。妇科癌症的治疗应根据具体情况决定,同时考虑当地COVID-19感染率和医疗设施的可用性。如果考虑推迟治疗,预后也是一个重要的考虑因素。如果可能,应采用标准治疗和正常时间框架。若无法做到,则最多推迟八周或转诊至另一中心是可接受的替代方案。